Concerns about Elon Musk’s alleged drug use have surfaced, causing unease among executives and board members overseeing the companies he leads, as reported by The Wall Street Journal. Anonymous sources familiar with Musk and his enterprises suggest ongoing use of ketamine, despite Musk’s statement last August that he holds a prescription for the drug as an antidepressant.

The report details a history of Musk’s alleged consumption of LSD, cocaine, ecstasy, and psychedelic mushrooms, primarily at private gatherings. In response to these claims, Musk’s lawyer emphasized that the billionaire undergoes regular and random drug testing at SpaceX, consistently passing without issue.

Also Read: Jiwani Drug Smuggling Attempt Thwarted by Pakistan Coast Guards

Musk’s public use of marijuana alongside podcaster Joe Rogan in 2018 triggered a review of his federal security clearance by the Pentagon, given his role as CEO of SpaceX. Elon Musk addressed the allegations on Twitter, stating, “After that one puff with Rogan, I agreed, at NASA’s request, to do 3 years of random drug testing. Not even trace quantities were found of any drugs or alcohol.”

The report also suggested that Tesla director Linda Johnson Rice, in office since 2017, chose not to seek reelection due to frustration with Musk’s behavior and alleged drug use.

Elon Musk oversees a diverse portfolio of six companies: Tesla, SpaceX, Twitter, The Boring Co., Neuralink, and xAI, an artificial intelligence startup. The revelation of Musk’s purported drug use adds a layer of scrutiny to the entrepreneur’s leadership across these ventures.